Targeting TBK1 to overcome resistance to cancer immunotherapy
Yi Sun(Broad Institute), Russell W. Jenkins(Broad Institute)
Cited by 165
Related Papers
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade
|Journal of Clinical Investigation|2020|73
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
|Cancer Immunology Research|2025|15